Form 10-Q · Quarterly report
IQVIA 10-Q, filed Oct 27, 2026
- Filed
- CIK
- 0001478242
- Accession no.
- 0001628280-26-067646
Summary
IQVIA reported third-quarter 2026 revenue of $4.43 billion, up 8.0% from a year earlier, and nine-month revenue of $12.95 billion, up 8.4%, with constant-currency growth of 8.6% and 7.7% respectively. Effective January 1, 2026, the company consolidated its reporting into two segments — Commercial Solutions and Research & Development Solutions — after folding Contract Sales & Medical Solutions into the former Technology & Analytics Solutions segment and moving certain Real-World offerings into the clinical research business.
Key points
- Third-quarter revenue rose $328 million to $4,428 million, with $132 million of the increase from Commercial Solutions and $221 million from Research & Development Solutions.
- Cost of revenues, excluding depreciation and amortization, was $2,930 million, or 66.2% of revenues, in the quarter.
- Restructuring costs were $36 million in the quarter and $150 million over the first nine months, tied to efforts to streamline global operations, cut overcapacity and integrate acquisitions, with actions expected through 2026 and into 2027.
- The effective income tax rate was 19.7% in the third quarter of 2026 versus 18.6% a year earlier, and interest expense rose to $203 million from $189 million on higher debt balances.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.